Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
REHOVOT, Israel, and BRIDGEWATER, N.J., Feb. 13, 2018 -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will report its financial results for the quarter and year ended December 31, 2017, after the market close on Tuesday, February 27. Foamix will host a conference call and webcast at 8:30am Eastern Time on Wednesday, February 28.
| Conference Call & Webcast | |
| Wednesday, February 28 @ 8:30am Eastern Time | |
| Toll Free: | 800-289-0438 |
| International: | 323-794-2423 |
| Conference ID: | 2903389 |
| Webcast: | http://public.viavid.com/index.php?id=128361 |
| Replays, Available through March 14: | |
| Toll-Free: | 844-512-2921 |
| International: | 412-317-6671 |
| Conference ID: | 2903389 |
About Foamix Pharmaceuticals Ltd.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX102 for the treatment of impetigo, FMX103 for the treatment of rosacea and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.
In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.
Contact:
Ilan Hadar, CFO & Country Manager
Foamix Pharmaceuticals Ltd.
+972-8-9316233
[email protected]
US Investor Relations
Michael Rice
LifeSci Advisors, LLC
646-597-6979
[email protected]
